Log In
Print
BCIQ
Print
Print this Print this
 

Kengreal, Kengrexal, cangrelor (formerly AR-C69931MX)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionReversible purinergic receptor P2Y G protein-coupled 12 (P2RY12; P2Y12) antagonist
Molecular Target Purinergic receptor P2Y G protein-coupled 12 (P2RY12) (P2Y12)
Mechanism of ActionPurinergic receptor P2Y G protein-coupled 12 (P2RY12) (P2Y12) antagonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$60.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today